Editor's Pick
The San Jose, California-based company has developed AccuScan, which analyzes a patient's circulating tumor DNA but does not require bespoke reagents.
The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.
Hackensack Meridien Health Launches Cancer Risk, Early Detection Program; Eyes Multi-Cancer Testing
Premium
Patients will be offered germline genetic testing after an assessment that includes genetic, lifestyle, and other clinical risk factor analysis.
Previse Completes Validation Study of Barrett's Esophagus Test, Sees Path to Guideline Inclusion
Premium
The epigenetic risk stratification test demonstrated the potential to decrease surveillance among some patients and increase it among others.
Global organizations are calling for an increase in diagnostic tests — particularly point-of-care molecular assays — to meet the challenge of a new outbreak.